Valuation : China Isotope & Radiation Corporation

Market Cap 3.69B 4.32B 550M 473M 447M 407M 760M 52.61B 767M 5.32B 2.05B 26.69B 2.07B 2.02B 84.76B P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 3.81B 4.45B 568M 488M 461M 420M 785M 54.31B 792M 5.49B 2.11B 27.55B 2.13B 2.09B 87.49B EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
29/08 China Isotope & Radiation Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
28/08 China Isotope & Radiation Corporation Announces Resignation of Zhang Junqi as an Executive Director, A Member of the Strategy Committee of the Board and A Member of the Science and Technology Innovation Committee of the Board, Effective August 28, 2026 CI
28/08 China Isotope & Radiation Corporation Announces CEO Changes, Effective August 28, 2026 CI
06/07 China Isotope to Form JV With Associate MT
03/07 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
19/06 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
19/06 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
27/05 China Isotope Proposes Auditor Change MT
27/05 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
28/03 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
28/03 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
28/03 China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
20/03 China Isotope & Radiation to buy 51% stake in Hunan Huifeng Engineering Detection RE
1 day-1.93%
1 week-13.53%
Current month-20.44%
1 month-23.13%
3 months-27.23%
6 months-36.64%
Current year-34.50%
1 week 13.06
Extreme 13.06
15.3
1 month 13.06
Extreme 13.06
17.49
Current year 13.06
Extreme 13.06
24.28
1 year 13.06
Extreme 13.06
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
26.5
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Corporate Secretary - 30/08/2024
Corporate Secretary - 30/08/2024
Comptroller/Controller/Auditor 52 18/12/2015
Director TitleAgeSince
Director/Board Member 57 22/02/2017
Director/Board Member 54 28/06/2019
Director/Board Member 54 30/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%-13.53%-21.76%+4.17% 550M
-2.30%-1.25%+181.12%+371.62% 21.34B
-0.77%-4.31%-38.75%-22.84% 9.8B
-1.35%+5.00%+427.24%+40.16% 8.65B
+0.04%-5.06%-28.02% - 6.79B
-0.31%-0.58%+91.22%+51.19% 6.55B
-1.95%-4.25%-28.94%-22.04% 5.64B
+0.30%-2.10%-7.89%-20.53% 4.24B
-4.46%-8.28%+58.47%+71.78% 3.9B
+0.22%-0.80%-22.22%-30.00% 2.74B
Average -1.26%-4.26%+61.05%+49.28% 7.02B
Weighted average by Cap. -1.39%-2.51%+107.51%+132.15%

Financials

2024 2025
Net sales 7.57B 8.85B 1.13B 971M 916M 834M 1.56B 108B 1.57B 10.91B 4.2B 54.73B 4.24B 4.15B 174B 7.19B 8.4B 1.07B 921M 869M 792M 1.48B 102B 1.49B 10.35B 3.98B 51.94B 4.02B 3.93B 165B
Net income 407M 475M 60.59M 52.11M 49.16M 44.79M 83.73M 5.79B 84.49M 586M 225M 2.94B 228M 223M 9.33B 327M 383M 48.79M 41.96M 39.59M 36.06M 67.42M 4.66B 68.03M 471M 181M 2.37B 183M 179M 7.51B
Net Debt -109M -127M -16.23M -13.96M -13.17M -12M -22.43M -1.55B -22.63M -157M -60.37M -787M -60.95M -59.62M -2.5B 119M 139M 17.71M 15.23M 14.37M 13.09M 24.47M 1.69B 24.69M 171M 65.86M 859M 66.49M 65.04M 2.73B
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,655
Date Price Change Volume
11/09/26 HKD 13.23 -1.93% 69,200
10/09/26 HKD 13.49 -3.37% 433,200
09/09/26 HKD 13.96 -2.51% 275,000
08/09/26 HKD 14.32 -1.78% 403,800
07/09/26 HKD 14.58 -4.71% 271,200

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!